| A193 |
Rontalizumab Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus. |
.png)
|
| A194 |
Baylor patent anti-IFN alpha Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
|
|
| A195 |
Chinese CDC patent anti-Interferon Alpha Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
|
|
| A196 |
Anifrolumab Biosimilar(Anti-IFNAR1 Reference Antibody)
Featured
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research. |
.png)
|
| A197 |
Medarex patent anti-IFNAR-1 Biosimilar(Anti-IFNAR1 Reference Antibody)
Featured
|
|
|
| A198 |
Emapalumab Biosimilar（Anti-IFNg Reference Antibody）
Featured
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH). |
.png)
|
| A199 |
Fontolizumab Biosimilar(Anti-IFNg Reference Antibody)
Featured
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease. |
.png)
|
| A200 |
AMG-811 Biosimilar(Anti-IFNg Reference Antibody)
Featured
|
|
|
| A201 |
Talizumab Biosimilar(Anti-IgE Reference Antibody)
Featured
|
Talizumab (TNX 901) is an anti-IgE humanized IgG1 monoclonal antibody. |
.png)
|
| A202 |
Quilizumab Biosimilar(Anti-IgE (M1 prime) Reference Antibody)
Featured
|
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research. |
.png)
|
| A203 |
Xentuzumab Biosimilar(Anti-IGF-1 Reference Antibody)
Featured
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation. |
.png)
|
| A204 |
Teprotumumab Biosimilar(Anti-IGF1R / CD221 Reference Antibody)
Featured
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research. |
.png)
|
| A205 |
Robatumumab Biosimilar(Anti-IGF1R / CD221 Reference Antibody)
Featured
|
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research. |
.png)
|
| A206 |
Lonigutamab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC). |
.png)
|
| A207 |
Ganitumab Biosimilar (Anti-IGF1R / CD221 Reference Antibody )
Featured
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer. |
.png)
|
| A208 |
Figitumumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. |
.png)
|
| A209 |
Dalotuzumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo. |
.png)
|
| A210 |
Cixutumumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. |
.png)
|
| A211 |
Immunomedics patent anti-IGF-1R Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
|
|
| A212 |
DX-2647 Biosimilar（Anti-IGF-2 Reference Antibody）
Featured
|
|
|
| A213 |
BT-063 Biosimilar（Anti-IL-10 Reference Antibody）
Featured
|
|
|
| A214 |
Ebdarokimab Biosimilar（Anti-IL-12b Reference Antibody）
Featured
|
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells. |
.png)
|
| A215 |
Lebrikizumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used for the research of asthma. |
.png)
|
| A217 |
IMA-026 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A218 |
GSK 679586 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A219 |
Abrezekimab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma. |
.png)
|
| A220 |
Cendakimab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). |
.png)
|
| A221 |
Dectrekumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research. |
.png)
|
| A222 |
CNTO 607 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A223 |
Tralokinumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD). |
.png)
|
